Skip To Main Content

BRAF inhibitor (3)

Melanoma

Phase I

A study to evaluate the safety, tolerability, processing by the body and effectiveness against BRAF-mutated solid tumours or melanoma of RO7276389 by itself or in combination with cobimetinib

ISRCTN13713551

Solid Tumor

Phase I

A study to evaluate the safety, tolerability, processing by the body and effectiveness against BRAF-mutated solid tumours or melanoma of RO7276389 by itself or in combination with cobimetinib

ISRCTN13713551